FDA Pipeline Preview, February 2012 (Bristol-Myers Squibb, AstraZeneca, Columbia Laboratories, Watson Pharmaceuticals, Achillion, Catalyst Pharmaceutical Partners, AlloCure, Neurocrine Biosciences, AiCuris, CanBas, Pinnacle Biologics, Ikaria)

February 1, 2012

Recent FDA action (through January 2012) related to dapagliflozin, progesterone vaginal gel 8%, ACH-1625 protease inhibitor, CPP-115 GABA aminotransferase inhibitor, AC607, NBI-98854 VMAT2 inhibitor, AIC246 inhibitor, CBP501, Porfimer sodium, inhaled nitric oxide, carbamazepine extended-release capsules, levetiracetam extended-release tablets

Complete response

Not recommended forapproval

Orphan drug designations